Optimal solutions for a model of tumor anti-angiogenesis with a penalty on the cost of treatment

@article{UrszulaLedzewicz2009,
abstract = {The scheduling of angiogenic inhibitors to control a vascularized tumor is analyzed as an optimal control problem for a mathematical model that was developed and biologically validated by Hahnfeldt et al. [Cancer Res. 59 (1999)]. Two formulations of the problem are considered. In the first one the primary tumor volume is minimized for a given amount of angiogenic inhibitors to be administered, while a balance between tumor reduction and the total amount of angiogenic inhibitors given is minimized in the second formulation. The optimal solutions to both problems are presented and compared.},
author = {Urszula Ledzewicz, Vignon Oussa, Heinz Schättler},
journal = {Applicationes Mathematicae},
keywords = {optimal control; bang-bang and singular controls; cancer treatment; angiogenic inhibitors},
language = {eng},
number = {3},
pages = {295-312},
title = {Optimal solutions for a model of tumor anti-angiogenesis with a penalty on the cost of treatment},
url = {http://eudml.org/doc/279876},
volume = {36},
year = {2009},
}

TY - JOUR
AU - Urszula Ledzewicz
AU - Vignon Oussa
AU - Heinz Schättler
TI - Optimal solutions for a model of tumor anti-angiogenesis with a penalty on the cost of treatment
JO - Applicationes Mathematicae
PY - 2009
VL - 36
IS - 3
SP - 295
EP - 312
AB - The scheduling of angiogenic inhibitors to control a vascularized tumor is analyzed as an optimal control problem for a mathematical model that was developed and biologically validated by Hahnfeldt et al. [Cancer Res. 59 (1999)]. Two formulations of the problem are considered. In the first one the primary tumor volume is minimized for a given amount of angiogenic inhibitors to be administered, while a balance between tumor reduction and the total amount of angiogenic inhibitors given is minimized in the second formulation. The optimal solutions to both problems are presented and compared.
LA - eng
KW - optimal control; bang-bang and singular controls; cancer treatment; angiogenic inhibitors
UR - http://eudml.org/doc/279876
ER -